Integra LifeSciences
IART
257 hedge funds and large institutions have $4.67B invested in Integra LifeSciences in 2018 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 83 increasing their positions, 88 reducing their positions, and 31 closing their positions.
106% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $1.51M
77% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 31
20% more capital invested
Capital invested by funds: $3.9B → $4.67B (+$772M)
9% more funds holding
Funds holding: 235 → 257 (+22)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 88
7.46% less ownership
Funds ownership: 90.04% → 82.58% (-7.5%)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.2M |
| 2 |
Millennium Management
New York
|
+$44.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$35.5M |
| 4 |
ClearBridge Investments
New York
|
+$23.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$23.1M |
Top Sellers
| 1 |
BlackRock
New York
|
-$121M |
| 2 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
-$34.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22.2M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$19.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$16.4M |
IART Hedge Fund Activity: Q2 2018 in Review
257 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2018, worth a combined $4.67B — up 20% from $3.9B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new IART positions and 31 closed out — a net gain of 24 holders — while 83 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $72.2M. The largest seller was BlackRock, cutting an estimated $121M.
- 257 institutional investors held Integra LifeSciences (IART) as of Q2 2018, up from 235 in Q1 2018.
- Funds reported $4.67B of Integra LifeSciences stock for Q2 2018, up 20% quarter-over-quarter.
- 55 funds opened new Integra LifeSciences positions in Q2 2018 and 31 closed out, a net change of +24 holders.
- The largest Integra LifeSciences buyer in Q2 2018 was Fidelity Investments, an estimated $72.2M added.
- The largest Integra LifeSciences seller in Q2 2018 was BlackRock, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2018.